Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Total Liabilities (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed Total Liabilities for 9 consecutive years, with $131.1 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities fell 9.28% to $131.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $131.1 million through Dec 2025, down 9.28% year-over-year, with the annual reading at $131.1 million for FY2025, 9.28% down from the prior year.
  • Total Liabilities for Q4 2025 was $131.1 million at Denali Therapeutics, up from $129.4 million in the prior quarter.
  • The five-year high for Total Liabilities was $442.6 million in Q1 2023, with the low at $115.5 million in Q2 2024.
  • Average Total Liabilities over 5 years is $263.8 million, with a median of $146.6 million recorded in 2024.
  • The sharpest move saw Total Liabilities surged 201.1% in 2021, then crashed 71.62% in 2024.
  • Over 5 years, Total Liabilities stood at $441.9 million in 2021, then fell by 5.44% to $417.8 million in 2022, then crashed by 70.57% to $123.0 million in 2023, then increased by 17.51% to $144.5 million in 2024, then dropped by 9.28% to $131.1 million in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $131.1 million, $129.4 million, and $139.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.